Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 0.77 |
| ▸ | ACE | P12821 | 14/20 | 0.77 |
| ▸ | CPA1 | P15085 | 2/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511466 | 1.00 | MME (0.77) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL8028693 | 1.00 | MME (0.77) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL6439617 | 1.00 | MME (0.77) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL8018074 | 0.91 | MME (0.83) | MMEACECPA1ACE2PIN1 | |
| SCHEMBL8027544 | 0.91 | MME (0.83) | MMEACECPA1ACE2PIN1 | |
| SCHEMBL27441337 | 0.91 | MME (0.83) | MMEACECPA1ACE2PIN1 | |
| SCHEMBL8026924 | 0.89 | MME (0.76) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL8030644 | 0.89 | MME (0.76) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL7568461 | 0.88 | MME (0.67) | MMEACECPA1ACE2ITGB1 | |
| SCHEMBL8016985 | 0.88 | MME (0.81) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | MME 76/4885ACE 1/4885CPA1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.